Find information on thousands of medical conditions and prescription drugs.

Glycogen storage disease type II

Glycogen storage disease type II (also called Pompe disease or infantile acid maltase deficiency) is a rare genetic disorder caused by a deficiency in the enzyme acid alpha-glucosidase (GAA), which is needed to break down glycogen, a stored form of sugar used for energy. It is the only glycogen storage disease with a defect in lysosomal metabolism, and was the first glycogen storage disease to be identified—in 1932. The build-up of glycogen causes progressive muscle weakness throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver and nervous system. Transmission is by autosomal recessive inheritance. more...

Home
Diseases
A
B
C
D
E
F
G
Galactorrhea
Galactosemia
Gardner's syndrome
Gastric Dumping Syndrome
Gastroesophageal reflux
Gaucher Disease
Gaucher's disease
Gelineau disease
Genu varum
Geographic tongue
Gerstmann syndrome
Gestational trophoblastic...
Giant axonal neuropathy
Giant cell arteritis
Giardiasis
Gigantism
Gilbert's syndrome
Gilles de la Tourette's...
Gingivitis
Gitelman syndrome
Glanzmann thrombasthenia
Glioblastoma
Glioblastoma multiforme
Glioma
Glomerulonephritis
Glossodynia
Glossophobia
Glucagonoma
Glucose 6 phosphate...
Glutaryl-CoA...
Glycogen storage disease
Glycogen storage disease...
Glycogen storage disease...
Glycogenosis type IV
Glycosuria
Goiter
Goldenhar syndrome
Goodpasture's syndrome
Graft versus host disease
Granulocytopenia
Graves' disease
Great vessels transposition
Growth hormone deficiency
Guillain-Barré syndrome
Gymnophobia
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Children have a 1 in 4 chance of inheriting the disease when both parents carry the abnormal gene. It is estimated to occur in about 1 in 40,000 births.

Variants

Pompe disease has three forms defined by age of onset and progression of symptoms:

Infantile, or early onset, is noticed shortly after birth. Symptoms include severe lack of muscle tone, weakness, and enlarged liver and heart. Mental function is not affected. Development appears normal for the first weeks or months but slowly declines as the disease progresses. Swallowing may become difficult and the tongue may protrude and become enlarged. Most children die from respiratory or cardiac complications before 2 years of age.

Juvenile onset symptoms appear in early to late childhood and include progressive weakness of respiratory muscles in the trunk, diaphragm and lower limbs, as well as exercise intolerance. Intelligence is normal. Most patients do not live beyond the second or third decade of life.

Adult onset symptoms also involve generalized muscle weakness and wasting of respiratory muscles in the trunk, lower limbs, and diaphragm. Many patients report respiratory distress, headache at night or upon waking, diminished deep tendon reflexes, and proximal muscle weakness, such as difficulty in climbing stairs. Intellect is not affected. A small number of adult patients live without major symptoms or limitations

Treatment

Cardiac and respiratory complications are treated symptomatically. Physical and occupational therapy may be beneficial for some patients. Alterations in diet may provide temporary improvement but will not alter the course of the disease. Genetic counseling can provide families with information regarding risk in future pregnancies.

Prognosis

The prognosis for individuals with Pompe disease varies according to the onset and severity of symptoms. The disease is particularly lethal in infants and young children.

Read more at Wikipedia.org


[List your site here Free!]


Liver-directed strategies and immunologic consequences of recombinant AAV-mediated cross-correction of glycogen storage disease type II : (Dissertation) $55.00

Glycogen storage diseases
Glycogen serves as the primary fuel reserve for the body's energy needs. Glycogen storage diseases, also known as glycogenoses, are genetically linked metabolic disorders that involve the enzymes regu
Caring for children with type 2 diabetes
Drug News The incidence of Type 2 diabetes, once called adult-onset diabetes, among American children is increasing. Although the exact number of children ...
Polycystic Ovary Syndrome and a Low Glycemic Index Diet
INTRODUCTION Polycystic ovary syndrome (PCOS), a combination of metabolic, endocrine and reproductive irregularities, may be the most common endocrine ...
Rhabdomyolysis associated with quinacrine therapy in a patient with chronic cutaneous lupus erythematosus
Abstract We describe a patient who developed rhabdomyolysis 6 weeks after starting combination therapy with hydroxychloroquine and quinacrine for the treatment of chronic cutaneous lupus erythema
ENZYMES: Genzyme, Pharming Tackle Pompe's Disease
Genzyme General (1 Kendall Square, Cambridge, MA 02139-1562; Tel: 617/252-7500) and Pharming Group N.V. (Leiden, Netherlands) are forming a joint venture ...
Hepatic encephalopathy
Hepatic encephalopathy (HE) is a brain disorder caused by chronic liver failure, particularly in alcoholics with cirrhosis, which results in cognitive, ...
A waist is a terrible thing to mind: central obesity, the metabolic syndrome, and sleep apnea hypopnea syndrome - editorials
In this issue of CHEST (see page 829), Schafer and colleagues report on a consecutive sample of men who had been referred for suspected sleep apnea-hypopnea ...
Overview: What is insulin resistance?
Insulin evokes a broad array of metabolic responses and, accordingly, can potentially be defined in myriad ways within the many metabolic pathways regulated ...

Home Contact Resources Exchange Links ebay